Litca SR 450 Tablet contains lithium carbonate 450 mg, a mood stabilizer primarily indicated for the treatment and maintenance of bipolar disorder. Lithium carbonate is effective in managing acute manic episodes and in preventing the recurrence of both manic and depressive phases. The sustained-release formulation ensures a gradual release of lithium, promoting steady plasma concentrations and minimizing peak-related side effects. The exact mechanism of action is not fully understood but is believed to involve modulation of neurotransmitter activity and intracellular signaling pathways, contributing to mood stabilization. Litca SR 450 is prescribed under careful medical supervision, with regular monitoring of serum lithium levels, renal function, and thyroid function to avoid toxicity and adverse effects such as tremors, polyuria, hypothyroidism, and gastrointestinal discomfort. Dose adjustments are individualized based on therapeutic response and serum levels, typically maintained within a narrow therapeutic window. Patients should be advised to maintain adequate hydration and avoid sudden changes in salt intake to prevent lithium toxicity. This medication is contraindicated in patients with severe renal or cardiovascular disease and should be used cautiously during pregnancy and lactation. Litca SR 450 Tablet is a critical component in the long-term management of bipolar disorder, improving patient quality of life by stabilizing mood fluctuations.